DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
USA - NYSE:DBD - US2536512021 - Common Stock
60.01 USD
-2.15 (-3.46%)
60.01 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to DBD. DBD was compared to 35 industry peers in the Technology Hardware, Storage & Peripherals industry. Both the profitability and the financial health of DBD get a neutral evaluation. Nothing too spectacular is happening here. DBD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year DBD was profitable.
DBD had a positive operating cash flow in the past year.
DBD had negative earnings in 4 of the past 5 years.
In multiple years DBD reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of DBD (1.36%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of 4.57%, DBD is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
DBD has a better Return On Invested Capital (8.85%) than 71.43% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DBD is significantly below the industry average of 16.16%.
The 3 year average ROIC (5.12%) for DBD is below the current ROIC(8.85%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROIC | 8.85% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
DBD's Profit Margin of 1.37% is in line compared to the rest of the industry. DBD outperforms 60.00% of its industry peers.
DBD has a Operating Margin of 7.47%. This is in the better half of the industry: DBD outperforms 77.14% of its industry peers.
In the last couple of years the Operating Margin of DBD has grown nicely.
DBD's Gross Margin of 25.48% is in line compared to the rest of the industry. DBD outperforms 42.86% of its industry peers.
DBD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), DBD is destroying value.
DBD has about the same amout of shares outstanding than it did 1 year ago.
DBD has less shares outstanding than it did 5 years ago.
The debt/assets ratio for DBD has been reduced compared to a year ago.
2.2 Solvency
DBD has an Altman-Z score of 1.92. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of DBD (1.92) is comparable to the rest of the industry.
The Debt to FCF ratio of DBD is 3.71, which is a good value as it means it would take DBD, 3.71 years of fcf income to pay off all of its debts.
DBD's Debt to FCF ratio of 3.71 is fine compared to the rest of the industry. DBD outperforms 68.57% of its industry peers.
DBD has a Debt/Equity ratio of 0.84. This is a neutral value indicating DBD is somewhat dependend on debt financing.
The Debt to Equity ratio of DBD (0.84) is worse than 62.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Altman-Z | 1.92 |
ROIC/WACC0.94
WACC9.41%
2.3 Liquidity
A Current Ratio of 1.36 indicates that DBD should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.36, DBD is in line with its industry, outperforming 48.57% of the companies in the same industry.
DBD has a Quick Ratio of 1.36. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.89, DBD is in line with its industry, outperforming 54.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
DBD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.07%.
DBD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 69.69% yearly.
The Revenue has decreased by -2.86% in the past year.
Measured over the past years, DBD shows a decrease in Revenue. The Revenue has been decreasing by -3.18% on average per year.
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
3.2 Future
The Earnings Per Share is expected to grow by 11.87% on average over the next years. This is quite good.
DBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.83% yearly.
EPS Next Y-3.97%
EPS Next 2Y13.81%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue Next Year2.09%
Revenue Next 2Y2.32%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.40, the valuation of DBD can be described as correct.
77.14% of the companies in the same industry are more expensive than DBD, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.07, DBD is valued a bit cheaper.
DBD is valuated correctly with a Price/Forward Earnings ratio of 12.00.
Based on the Price/Forward Earnings ratio, DBD is valued a bit cheaper than the industry average as 65.71% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.08, DBD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.4 | ||
| Fwd PE | 12 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DBD indicates a rather cheap valuation: DBD is cheaper than 94.29% of the companies listed in the same industry.
DBD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. DBD is cheaper than 82.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.74 | ||
| EV/EBITDA | 7.14 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.81%
EPS Next 3Y11.87%
5. Dividend
5.1 Amount
No dividends for DBD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
60.01
-2.15 (-3.46%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners105.22%
Inst Owner Change-2.7%
Ins Owners1.78%
Ins Owner Change0%
Market Cap2.20B
Revenue(TTM)3.69B
Net Income(TTM)50.60M
Analysts82.86
Price Target77.18 (28.61%)
Short Float %2.35%
Short Ratio4.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)0%
PT rev (3m)4.61%
EPS NQ rev (1m)7.83%
EPS NQ rev (3m)16.15%
EPS NY rev (1m)-0.41%
EPS NY rev (3m)4.56%
Revenue NQ rev (1m)-0.97%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.4 | ||
| Fwd PE | 12 | ||
| P/S | 0.6 | ||
| P/FCF | 8.74 | ||
| P/OCF | 7.87 | ||
| P/B | 1.99 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.14 |
EPS(TTM)3.66
EY6.1%
EPS(NY)5
Fwd EY8.33%
FCF(TTM)6.87
FCFY11.45%
OCF(TTM)7.63
OCFY12.71%
SpS100.75
BVpS30.23
TBVpS-9.36
PEG (NY)N/A
PEG (5Y)N/A
Graham Number49.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROCE | 11.2% | ||
| ROIC | 8.85% | ||
| ROICexc | 9.91% | ||
| ROICexgc | 29.15% | ||
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% | ||
| FCFM | 6.82% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 20.59% | ||
| Cap/Sales | 0.75% | ||
| Interest Coverage | 2.89 | ||
| Cash Conversion | 68.06% | ||
| Profit Quality | 497.23% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | 1.92 |
F-Score7
WACC9.41%
ROIC/WACC0.94
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
EPS Next Y-3.97%
EPS Next 2Y13.81%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
Revenue Next Year2.09%
Revenue Next 2Y2.32%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.77%
EBIT Next 3Y13.69%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%
DIEBOLD NIXDORF INC / DBD FAQ
What is the fundamental rating for DBD stock?
ChartMill assigns a fundamental rating of 4 / 10 to DBD.
What is the valuation status for DBD stock?
ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.
What is the profitability of DBD stock?
DIEBOLD NIXDORF INC (DBD) has a profitability rating of 4 / 10.
How financially healthy is DIEBOLD NIXDORF INC?
The financial health rating of DIEBOLD NIXDORF INC (DBD) is 4 / 10.
Can you provide the dividend sustainability for DBD stock?
The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.